Fintel reports that on June 13, 2024, Rodman & Renshaw initiated coverage of Heron Therapeutics (NasdaqCM:HRTX) with a Buy recommendation.
Analyst Price Forecast Suggests 89.41% Upside
As of June 12, 2024, the average one-year price target for Heron Therapeutics is 6.88. The forecasts range from a low of 5.05 to a high of $9.45. The average price target represents an increase of 89.41% from its latest reported closing price of 3.64.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Heron Therapeutics is 220MM, an increase of 66.82%. The projected annual non-GAAP EPS is -0.33.
What is the Fund Sentiment?
There are 288 funds or institutions reporting positions in Heron Therapeutics. This is an increase of 10 owner(s) or 3.60% in the last quarter. Average portfolio weight of all funds dedicated to HRTX is 0.14%, an increase of 108.65%. Total shares owned by institutions increased in the last three months by 4.22% to 125,670K shares. 
The put/call ratio of HRTX is 0.10, indicating a bullish outlook.
What are Other Shareholders Doing?
Rubric Capital Management holds 26,714K shares representing 17.73% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 10,112K shares representing 6.71% ownership of the company. In its prior filing, the firm reported owning 5,929K shares , representing an increase of 41.37%. The firm increased its portfolio allocation in HRTX by 154.44% over the last quarter.
Velan Capital Investment Management holds 6,987K shares representing 4.64% ownership of the company. No change in the last quarter.
Franklin Resources holds 6,375K shares representing 4.23% ownership of the company. In its prior filing, the firm reported owning 6,405K shares , representing a decrease of 0.47%. The firm decreased its portfolio allocation in HRTX by 81.01% over the last quarter.
Tejara Capital holds 4,412K shares representing 2.93% ownership of the company. In its prior filing, the firm reported owning 5,275K shares , representing a decrease of 19.58%. The firm increased its portfolio allocation in HRTX by 19.54% over the last quarter.
Heron Therapeutics Background Information
(This description is provided by the company.)
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
